Antisense strategies for treatment of heart failure.
Harding
Sian E
SE
National Heart and Lung Institute, Imperial College, London, UK.
del Monte
Federica
F
Hajjar
Roger J
RJ
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000628:therapy; D002135:Calcium-Binding Proteins / Q000096:biosynthesis; D000252:Calcium-Transporting ATPases / Q000235:genetics; D015536:Down-Regulation; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D032383:Myocytes, Cardiac / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D011485:Protein Binding; D011817:Rabbits; D051381:Rats; D011943:Receptors, Adrenergic, beta / Q000378:metabolism; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; D013997:Time Factors; D000099211:Phospholamban
D002135:Calcium-Binding Proteins; D000252:Calcium-Transporting ATPases; D016376:Oligonucleotides, Antisense; D011943:Receptors, Adrenergic, beta; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; D000099211:Phospholamban